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OBJECTIVE: To implement a selective and sensitive analytical method to quantify morphine in small volumes of plasma by gas-
liquid chromatography-mass spectrometry (GC-MS), aimed at post-operatively monitoring the drug.
METHOD: A gas-liquid chromatographic method with mass detection has been developed to determine morphine concentration 
in plasma after solid phase extraction. Morphine-d3 was used as an internal standard. Only 0.5 mL of plasma is required for the 
drug solid-phase extraction in the Bond Elut-Certify®, followed by the quantification of morphine derivative by GC-MS using a 
linear temperature program, a capillary fused silica column, and helium as the carrier and make-up gas. The method was applied to 
determine morphine content in plasma samples of four patients during the postoperative period of cardiac surgery. Patient-controlled 
analgesia with morphine was performed by a venous catheter, and a series of venous blood samples were collected. After the oro-
tracheal extubation, morphine plasma levels were monitored for up to 36 hours. 
RESULTS: The run time was 16 minutes because morphine and the internal standard were eluted after 8.8 minutes. The GC-MS 
method had 0.5 -1000 ng/mL linearity range (r2=0.9995), 0.1 ng/mL limit of detection, intraday and interday precision equivalent 
to 1.9% and 6.8%, and 0.1% and 0.8% systematic error (intraday and interday, respectively). The analytical method showed optimal 
absolute (98%) and relative (100.7%) recoveries. Morphine dose requirements and plasma levels are discussed. 
CONCLUSION: The analytical gas-liquid chromatography-mass spectrometry method is selective and adequate for morphine 
measurements in plasma for applications in clinical studies.
KEYWORDS: Morphine. Plasma monitoring. Gas chromatography-mass spectrometry. post operative period. Dose requirements.
INTRODUCTION
Opiates are the drugs of choice for short-term treatment 
of post-surgical and traumatic pain as well as for long-
term treatment of severe pain in cancer patients. Because 
morphine is the most potent painkiller, it is the reference 
by which analgesics are assessed.1 Particularly for surgical 
patients, it has been extensively reported that pain and 
anxiety may cause major discomfort, increase the risk for 
postoperative complications, and even prolong their hospital 
residence.2 The use of Patient-Controlled Analgesia (PCA) 
in hospitals has been a recent practice because of its proven 
advantages over conventional intramuscular injections. These 
include improved pain relief, greater patient satisfaction, less 
sedation, and fewer postoperative complications. Morphine 
is the most studied and most commonly used intravenous 
drug for PCA,3 but large or repeated doses can induce 
prolonged sedation, nausea, vomiting, apathy, reduced 
physical activity, dysphoria, constipation, hypotension and 
respiratory depression, which can lead to death.1,4
Although, several analytical methods for morphine 
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detection have been proposed, including radioimmunoassay,5,6 
gas chromatography (GC) with nitrogen–phosphorous 
detection, flame ionization detection and electron capture 
detection, GC–mass spectrometry (GC–MS) has unsurpassed 
sensitivity and selectivity.7-15 Many studies have used GC–MS 
as an analytical tool, but sample preparation is very laborious, 
and no study has achieved the sensitivity required for 
pharmacokinetic studies of low doses of morphine.13,15-22
The aim of the present study was to implement a 
selective and sensitive GC-MS method to determine plasma 
morphine for application in clinical studies. Typically, plasma 
concentrations in such studies range from 1 to 20 ng/mL and 
involve the processing of a large a number of samples. 
MATERIALS AND METHODS
Chemical and reagents
Morphine sulphate pentahydrate (M-8777) was purchased 
from Sigma Aldrich (MO, USA), and the internal standard 
Morphine-(N-methyl-d3), used at 10 µg/mL in methanolic 
solution (M-006 RADIAN®), was obtained from Cerilliant 
(TX, USA).
Bis(trimethylsilyl)trifluoroacetamide (BSTFA) T-6381, 
the derivatizing agent, was purchased from Sigma Aldrich 
(MO, USA). The siliconizing agent, dimethylchlorosilane 
(DMCS) D-6258, was obtained from Sigma Aldrich (MO, 
USA). All other solvents and reagents of analytical grade 
were from Merck (Sao Paulo, Brazil). Water was purified 
by a Simplicity Milli-Q system from Millipore (Sao Paulo, 
Brazil). High purity helium was analytical grade 5.0, purity 
99.999%, and was obtained from White Martins (Sao Paulo, 
SP, Brazil).
The solid phase extraction apparatus consisted of a 
solid phase cartridge Bond Elut-Certify®, 50 mg, 50/PK, 
Varian-12105030 (CA, USA) attached to a vacuum system 
Welch Vacuum® (IL, USA ). In addition, a conic Becker 
model 13222, a Reacti-Vap 18780 and a Reacti-Therm 
18870 system, all supplied by Pierce (IL, USA) were used 
to obtain the morphine derivative.
Instrumentation 
Analyses were performed in a Hewlett-Packard 6890 
Series GC (LP, USA) equipped with a splitless injector and 
a 6890 Series mass selective detector (MSD) in EI mode (70 
eV) from Hewlett-Packard (LP, USA). 
The column was a 30 m, 5% phenyl methyl siloxane 
capillary column HP-5MS Hewlett-Packard (LP, USA) with 
an internal diameter of 0.25 mm and a film thickness of 0.25 
mm. The morphine and internal standard peak:area ratios 
were plotted using an HP Deskjet 890C, Hewlett-Packard 
(Sao Paulo, Brazil). 
Chromatographic conditions
High purity helium was used as the carrier gas at a 
constant flow-rate of 0.6 mL/min (constant pressure, 7 psi) 
and as a make-up gas for the mass detector at a constant 
flow of 0.2 mL/min. The injector and detector temperatures 
were maintained at 250°C and 280°C, respectively. The oven 
temperature was programmed as follows: 150°C for 1 min 
after injection, increasing to 250°C at 20°C/min, and finally 
holding at 250°C for 8 min (overall run time 13 min and 
recovery time 3 min). The MSD was operated in the selected-
ion monitoring mode (SIM) using m/z equivalent to 429.0 and 
432.0 for the morphine and morphine d3 (internal standard), 
respectively; each ion had a dwell time of 100 ms.
Preparations of standards and internal controls
Stock solutions of morphine were prepared by dissolving 
the appropriate amount of standard in pure water to yield a 
final drug concentration of 1 mg/mL, free base. Linearity 
was investigated by adding an appropriate volume from the 
stock solutions to drug-free plasma to obtain the following 
concentrations of morphine in plasma: 1000, 880, 440, 220, 
110, 55, 23, 11, 6, 3, 1 and 0.5 ng/mL, with the calibration 
curve plotted daily by serial dilution in the range 0.5 - 440 
ng/mL. Internal quality controls were prepared by diluting 
the stock solution in drug-free plasma to obtain high 
(400 ng/mL), medium (200 ng/mL) and low (10 ng/mL) 
concentrations. 0.5mL aliquots of the standards in plasma 
were distributed in Eppendorf tubes and stored at -20°C 
until assay.
Morphine d3, internal standard (IS) and stock solutions 
were prepared to obtain 1mg/mL in methanol, distributed in 
Eppendorf tubes, and stored at –20ºC. The working solution 
of the internal standard was prepared daily from the stock 
solution to obtain a concentration of 10 µg/mL. 
Bis-(trimethylsilyl)-trifluoroacetamide (BSTFA) was 
sealed in Sigma Aldrich T6381 ampoules (1 mL) and kept 
in the refrigerator. Dimethylchlorosilane (DMCS), 10%, was 
prepared by dissolving 1 g with 10 mL of hexane.
Sample extraction procedure
Preparation of glassware
Glassware was siliconized by immersion in a 10% 
solution of dimethylchlorosilane in n-hexane for 60 min, 
rinsing with methanol and then acetone, and oven drying at 
60°C for 30 minutes.
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Solid-phase extraction and morphine elution
Plasma aliquots (0.5 mL), 0.5 mL of Tris buffer (pH 
9.5) and 25 µL of the working solution (morphine d3/
internal standard) were transferred to sample tubes. Solid 
phase extraction was performed with Bond Elut Certify 
(50 mg) cartridges. Each cartridge was first conditioned 
with 2 mL of methanol, followed by 2 mL of water, both at 
flow rate of 3 mL/min. After application of the samples at 
1 mL/min, the cartridges were washed with 2 mL of water, 
followed by 1 mL of acetate buffer (50 mM, pH 4), and 
then 2 mL of methanol. Then, the cartridges were dried 
with a 10 mL stream of air, and morphine was eluted with 
2 mL of a freshly prepared mixture of solvents consisting 
of dichlormethane, isopropylic alcohol and ammonium 
hydroxyde (20:5:0.5, v/v). The purified extract eluted from 
the solid phase extraction was transferred to a previously 
siliconized derivatization Becker (reaction vial from Pierce, 
code 13222, IL, USA), and the solvents from the eluate 
were evaporated to dryness (heating block at 40oC) for later 
derivatization.
Derivatization
The purified dried extract was added to 50 µL BSTFA 
agent. The derivatization was performed at 70°C for 20 
minutes in a Reacti-Vap model 18780, Reacti-Therm 
model 18870, both supplied by Pierce (IL, USA). The 
solution was concentrated under a stream of nitrogen, and the 
2 µL aliquots were injected into the GC–MS equipment.
Linearity, calibration curve and calculation procedures 
The nominal value of plasma morphine was plotted as a 
function of the peak area ratio obtained from morphine and its 
internal standard (morphine d3) versus the drug concentration. 
The linearity of the method was determined in triplicate for 
each concentration ranging from 0.5 to 1000 ng/mL.
The linear regression line and the estimated linear 
correlation coefficient were used in the calibration curve 
(equation: y = b + ax, where x is the peak area ratio, a is 
the slope and b is the intercept). According to the current 
local regulations for bioanalytical methods, at least five 
of the total amount of calibrators (0.5, 1, 3, 6, 11, 23, 55, 
110, 220 and 440 ng/mL) must be considered for the plot 
of the daily calibration curve. The daily curve was accepted 
if at least 7/10 of the internal controls (high, medium and 
low concentrations analysed in triplicate) presented a 
systematic error lower than 15%. At least one control at each 
concentration was required to be within the acceptable range. 
Once accepted, the calibration curve was used to estimate the 
drug concentration in samples from patients. The linearity of 
the method was determined in triplicate at each concentration 
ranging from 0.5 to 1000 ng/mL.
Accuracy, precision and recovery
The precision of the method was defined as the degree 
of agreement among individual tests when the procedure 
was applied repeatedly and multiple replicates at three 
different concentrations were analysed and expressed 
as the coefficient of variation (CV %) from the back-
calculated value subtracted from the target value and then 
divided by the target value, expressed as a percentage. The 
intra-day precision was evaluated by analysis in triplicate 
of the high (1000 ng/mL), medium (400 ng/mL) and low 
(10 ng/mL) concentrations. The inter-day precision was 
determined by analysis in triplicate of the high, medium 
and low concentrations of morphine on three different days 
(n=27). 
Accuracy was evaluated by the analysis of multiple 
replicates in three different concentrations and expressed as a 
percentage of inaccuracy or systematic error. This parameter 
was estimated by the value of the mean back-calculated 
concentrations divided by the theoretical concentrations, 
expressed as percentage. The intra-day accuracy was 
evaluated by triplicate analysis of the high (1000 ng/mL), 
medium (400 ng/mL) and low (10 ng/mL) concentrations. 
The inter-day inaccuracy was determined by analysis of 
the high, medium and low concentrations of morphine in 
triplicate on three different days (n=27).
Absolute recovery of morphine from plasma was 
estimated by the peak area integrated for morphine in 
the plasma assayed versus the peak area integrated, after 
direct injection, expressed as a percentage. The efficiency 
of the relative recovery of the drug in plasma assayed 
according to the extraction procedure was estimated by 
the peak:area ratio obtained for morphine relative to its 
internal standard.
Specificity 
The specificity of an analytical method is its ability to 
accurately measure an analyte in the presence of endogenous 
compounds. Specificity was evaluated by the analysis of 
drug-free plasma samples (normal, haemolysed, lipemic 
and icteric sample biological matrices) and applying the 
analytical procedure.
Limits of detection and quantification
The limits of detection (LOD) and quantification (LOQ) 
were determined based on the analysis of ten replicates. The 
LOQ was defined as the lowest drug plasma concentration 
of the daily calibration curve that could be determined with 
an accuracy of 80-120% and precision lower than 20%. LOD 
had a signal to noise ratio equivalent to 2:1, while the LOQ 
had a ratio of 10:1.
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Stability study
To determine the stability of morphine in plasma, 
variations of less than 15% for all the concentrations studied 
were accepted for use. The stability study consisted of the 
following assessments:
•	 Spiked blank plasma samples were analysed after three 
freeze/thaw cycles by GC-MS in the same sequence after 
cleaning up the plasma samples as detailed above, using 
two different concentrations of morphine in plasma (10 
and 400 ng/mL) analysed in triplicate during three con-
secutive periods. Data were expressed as percentage of 
systematic error or inaccuracy. The acceptance criterion 
for all concentrations studied was set as less than 10% 
variation.
•	 Conditions for the analysis were determined from sam-
ples extracted in triplicate at three concentrations (10, 
400 and 1000 ng/mL) and kept at room temperature after 
derivatization for the maximum time the sample could 
remain under these condition. The concentration obtained 
was expressed as a percentage of the nominal value.
•	 Short term stability: Two different morphine concen-
trations (400 and 10 ng/mL) were used. The controls 
remained at room temperature for 6 hours, and then were 
examined by the method described.
•	 Long term stability at -20oC: Three concentrations were 
used in triplicate for different periods of time to ensure 
stability throughout the course of the study.
Robustness
The robustness of the method was determined using 
slight variations in the flow of gas for drag (± 0.05 mL/min). 
The study was developed using six replicates, and results 
were expressed as a function of the coefficient of variation. 
Clinical study design
Serial blood samples were collected from venous 
catheters of four patients during the postoperative period 
after extubation at the following time points: 3, 6, 12, 18, 
24 and 36 hrs. Heparinized blood collecting tubes were 
centrifuged at 1500 g for 15 min. The plasma was separated 
and stored at -20°C until analysis. The study protocol 
was approved by the local ethics committees of the two 
institutions involved: the Department of Pharmacy and the 
Department of Medicine from the University of Sao Paulo, 
and written informed consent was obtained from each 
participant before inclusion in the trial. 
Four coronary artery bypass grafting surgery patients 
were investigated. Characteristics of patients and drug 
requirements (PCA) in the late postoperative period are 
shown in table 1.
RESULTS
Chromatography
Among the mass/charge (m/z) peaks (401, 414, 417, 429 
and 432), 429 and 432 are fingerprints for morphine and the 
morphine-d3 derivatives, respectively. The retention time 
was 8.8 minutes for both morphine and morphine-d3. Typical 
chromatograms of extracts obtained from the determinations 
of isolated morphine in plasma samples plus the internal 
standard (morphine d3) and the mass spectrum are shown 
in Fig. 1. To guarantee the high selectivity obtained, the 
total time required for each chromatographic run was 16 
minutes. 
The analysis of morphine content revealed excellent 
linearity and acceptable accuracy and precision (Table 2). 
Linearity was expressed by the intercept, and the slope of 
the linear function as the mean, with the respective standard 
error of the mean (SEM) as follows: intercept 0.0219 (SEM: 
0.002376), slope 0.0128 (SEM:0.000036); also it was 
considered the linear correlation coefficient (r2 0.9995) over 
the 0.5 -1000 ng/mL range, Fig. 2. The detection limit was 
0.1 ng/mL, and the quantification limit was 0.5 ng/mL based 
on the analysis of 0.5 mL plasma in 10 replicates. 
The method showed good sensitivity, linearity and 
stability, with acceptable accuracy and precision (Table 2). 
In addition, slight variations in the flow of gas for drag (± 
0.05 mL / min) showed a coefficient of variation of 3.6% 
(Table 2).
Analysis of the short-term stability of morphine (time 
and conditions of analysis) demonstrated that the drug in 
the plasma extract submitted to chromatography did not 
Table 1 - Demographic and somatic characteristics, drug requirements (PCA) and analgesia after extubation in the late 
postoperative period
Patient allocation Morphine PCA (mg) Gender Age (yrs) Weight (kg) Height (m) BMI (kg/m2)
# 04 13 F 41 48.0 1.50 21.33
# 11 10 M 63 88.0 1.72 29.75
# 15 26 M 76 67.6 1.64 25.13
# 30 72 M 64 69.1 1.61 26.66
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degrade within an 8 h period. The short term stability of 
morphine had a 0.5% coefficient of variation, and the long 
term stability of morphine had a 5.6% coefficient of variation 
(Table 2). Thaw cycles revealed good stability of the drug 
in biological samples after three consecutive freeze/thaw 
cycles. 
Therapeutic Drug Monitoring 
During PCA device drug bolus delivery in the 
postoperative period, morphine plasma levels, expressed as 
medians, were: 13.1 ng/mL (3rd hr), 18.9 ng/mL (6th hr), 53.0 
ng/mL (12th hr), 28.9 ng/mL (18th hr), 13.9 ng/mL (24th hr) 
and 15.4 ng/mL (36th hr) (Fig 3). Additionally, the fraction 
of morphine PCA consumed at time intervals up to 36 hours 
was considered to be even, as illustrated in Figure 3. The 
total amount of the drug delivered up to 36 hours, expressed 
as a median, was 19.5mg.
DISCUSSION
Morphine is the analgesic opiate most frequently used for 
short periods for treatment of post-surgical or trauma pain 
and even for long-term treatment to control severe pain in 
patients with cancer. Patient-controlled analgesia is preferred 
in such cases because the pump device can deliver 1-100 mg 
of morphine by intermittent boluses.6,12,23-25 
Several methods have been proposed to determine the 
morphine content in biological matrices, mainly in legal 
medicine for forensic toxicology purposes or in drug abuse 
control. Only a few methods, however, are adequate for 
analgesia clinical studies because a large degree of linearity 
and high sensitivity are required in the follow up of those 
patients receiving intravenous intermittent boluses of 
morphine.
Radioimmunoassay (RIA) is quite simple and sensitive 
but has a serious limitation because an important cross-
reaction of the main metabolites, morphine 3-glucuronide 
(M-3-G) and morphine 6-glucuronide (M-6-G), occurs 
with the polyclonal antibody.5,6 High performance liquid 
chromatography using electrochemical, chemoluminescence 
or fluorescence detection showed low sensitivity compared 
to RIA. Another limitation in the preparation of the organic 
extracts is the extensive procedure and long time required to 
clean up biological matrices. 26-29
Using gas chromatography to determine morphine 
content in biological matrices in combination with a flame 
ionisation detector, nitrogen-phosphorus detector or even 
Figure 1. Determination of plasma morphine concentration through CG-MS. Chromatograms: morphine and morphine - D3 (internal standard 250ng) 8.8 
minutes. Run 16 minutes. Mass spectrum: mass 429 (morphine); mass 432 (morphine D3).
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mass spectrometry (GC-MS) are the high sensibility and 
selectivity that facilitated its original application in forensic 
toxicology and drug abuse control.13,15-22 GC-MS is a suitable 
method to determine morphine content but requires an 
internal standard, in general a structural analogue such 
as nalorphine or morphine-d3.13,15,17-19,30-32 Concerning the 
purification of the biological matrices, Krogh et al. (1993) 
described a direct injection of the sample that was diluted, 
derivatized and injected in an automated CG-MS system. 
The method presented a serial of operational disadvantages 
caused by the direct injection of the biological matrix. 
Particularly for forensic purposes, Ropero-Miller et al. 
(2002) used the precipitation of proteins from whole blood 
with methanol, followed by solid phase extraction using 
cartridges CSDAU 206 (BRISTOL, PA). Meatherall et al. 
(2005) reported the precipitation of proteins with acetonitrile 
followed by liquid–liquid extraction using a mixture of 
chloroform and trifluoromethanol. Lower recoveries resulted 
from the clean up of biological matrices in both methods; the 
main disadvantage is that the low end of the sensitivity range 
reached 10 and 50 ng/mL.31-33 Liquid–liquid extraction of 
morphine from biological matrices was reported previously, 
but the required sensitivity for application in clinical trials 
was not achieved in most cases. 15-18,22,31 Jones et al. (1984) 
determined the morphine content in urine and tissues for 
forensic purposes with adequate sensitivity by GC-MS, in 
spite of the laborious sample clean up process. 34 
A solid phase extraction to clean up biological matrices 
was reported by Drost et al. (1984). These authors proposed 
the use of Bond Elut C18 cartridges to determine morphine 
content by GC-MS after derivatization with BSTFA. A 
low sensitivity, however, was obtained (5 ng/mL), and 
the linearity was inadequate. Then, a series of different 
cartridges were investigated to optimise the purification of 
biological matrices by solid phase extraction, none of which 
reached the sensitivity and linearity required for clinical 
studies.12,19-21,35,36 
Therefore, in the present study, we designed an 
analytical procedure to purify the biological matrix by 
solid phase extraction by applying Bond Elut Certify, 
50mg/3mL (Varian, CA, USA). These cartridges were able to 
concentrate morphine extracted from the reduced volume of 
plasma. An optimal absolute recovery (96.4%) was obtained 
for morphine, and its internal standard (morphined3) 
guaranteed adequate sensitivity (LOD: 0.1 ng/mL and 
LOQ:0.5 ng/mL), good precision and accuracy and also a 
large degree of linearity (0.5-1000 ng/mL). Additionally, 
our data are more suitable than those reported by Drost 
et al. (1984) using similar cartridges. The superiority of 
our procedure can be justified by the higher capacity of 
the selected cartridge (Bond Elut C18 Certify), which 
Table 2 - Confidence limits of analytical method to determine 
plasma morphine concentration
Parameter Unit Confidence Limits
Linearity ng/mL 0.5 - 1000
Linear regression coefficient (r2 = 0.9995)
Limit of quantification (n=10) ng/mL 0.5
Limit of detection (n=10) ng/mL 0.1
Precision (10,200,400ng/mL)
 Intra-day (mean) (%) 1.9
 Inter-days (mean) (%) 6.8
Systematic error (10,200,400ng/mL)
 Intra-days (mean) (%) 0.1
 Inter-days (mean) (%) 0.8
Stability (Thawing cycles)* (%) 3.5
Short-term stability * (%) -0.5
Long-term stability * (%) 5.6
Robustness flow rate (± 0.05 mL / min). (CV%) 3.6
Recovery
 Absolute (%) 96.4
 Relative (%) 100.7
* Systematic error expressed as percentage of inaccuracy. 
Figure 2 - Linearity of morphine concentration  in plasma (0.5-1000 ng/mL) 
Figure 3 - Curve of plasma concentrations of morphine obtained as a func-
tion of time after extubation in the group of study (n = 4) considering the 
dose of morphine PCA consumed at each interval. Population data expressed 
as medians: (__) plasma concentration,  (--) consumption of morphine up 
to 36 h.
electron capture detector has problems related to selectivity 
for morphine at low concentrations.7-15 The advantages to 
determining morphine content by gas chromatography-
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guaranteed higher recoveries of the drug during extraction 
from plasma samples. 
Because derivatization is required prior to GC-MS 
analysis, a series of agents was proposed previously, 
such as bis-(trimethylsilyl)-trifluoroacetamide/BSTFA, 
trifluoroacetyl anhydride (TFA),19 pentafluoropropionic 
anhydride (PFPA)13,18, heptafluorobutirate anhydride 
(HFBA)15 and methoxamine plus propionic anhydride.31 
The agent BSTFA was chosen in the present study and 
provided stable fragments, permitting GC-MS analysis for 
up to 8 hours after derivatization. The method validated in 
the present study showed results similar to data reported 
previously despite using different derivative agents. The 
higher sensitivity achieved in our study can be explained by 
the use of a fused silica capillary column that increases the 
sensitivity of the GC-MS method to analyze morphine, as 
discussed in previous studies.15,18,31-33 
Thawing cycles in the present study showed good 
stability for morphine in plasma samples, and they are in 
agreement with the data described by Leis et al., 2000. 
Finally, none of the procedures reported previously described 
the short term stability of morphine or its internal standard 
solutions in methanol and also in plasma samples. The 
robustness of the analytical method investigated in this study 
has no available previously reported data for comparison.
Finally, the present method is possibly more costly than 
most of the current analytical chromatographic assays, but, 
as is the case of most instrumental methods, the cost is 
significantly reduced as the number of analyses scales up. 
In addition, the intrinsic advantages of the present method 
certainly imply a gain in terms of the cost/benefit relation. 
Application of the GC-MS method to monitor mor-
phine plasma levels in post-surgical patients
After total morphine PCA delivered doses of 19.5 mg, 
plasma concentrations of morphine obtained by GC-MS in 
post-surgical patients expressed as medians were: 13.1 ng/
mL (3rd h), 18.9 ng/mL (6th h), 53.0 ng/mL (12th h), 28.9 ng/
mL (18th h), 13.9 ng/mL (24th h) and 15.4 ng/mL (36th h). The 
peak morphine plasma concentration was reached at the 12th 
hour and declined up to the 24th hour. Drug consumption in 
each period indicated that morphine consumption increases 
in the late postoperative period, between 24 and 36 hours.
In a previous clinical study, Dal et al. (2003) compared 
two groups of surgical patients with a morphine PCA device 
pump for analgesia purposes in the postoperative period after 
a coronary artery bypass graft. The first group of patients 
received morphine PCA, and a second group received a 
combination of morphine PCA plus a basal drug infusion. 
Drug plasma concentrations did not show a difference 
between groups: for group 1 and group 2, concentrations 
were 80 and 86 ng/mL (4th h), 86 and 119 ng/mL (20th h), 
115 and 153 ng/mL (28th h), 104 and 125 ng/mL (44th h), 
respectively. Additionally, the degree of analgesia between 
groups was not different, but the total morphine consumption 
between groups differed from the 28th h up to 44th h. 37
In the present study, our data show that morphine plasma 
concentrations during the postoperative period of cardiac 
surgery were lower than those reported by Dal et al 2003. In 
fact, these differences could be described as a consequence 
of the higher selectivity of our analytical procedure (GC-
MS) compared to the method reported previously, which was 
based on chemoluminescence measurements that determine 
the concentration of morphine plus its main metabolite, 
morphine-6-glucuronide. 37
CONCLUSION
The advantages of the method described in the present 
study include the selective determination of morphine 
using GC-MS, a reduced plasma volume requirement, high 
sensitivity due to optimal recovery of drug by solid phase 
extraction and robust chromatographic assay. In addition, 
the short run-time permits its application in clinical studies, 
including drug plasma monitoring, optimisation of PCA 
device for intermittent boluses delivery of morphine for short 
or long term periods and also for pharmacokinetic studies. 
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